Abstract
The bioavailability of two rilmenidine tablet formulations was compared in healthy
male (17) and female (8) subjects, aged 18 to 36 years, during a laboratory-blind,
randomized, two-treatment, two-period, cross-over study under fasting conditions.
In each treatment phase subjects received a single dose of 1.544 mg rilmenidine dihydrogen
phosphate (CAS 85409-38-7), equivalent to 1 mg rilmenidine (CAS 54187-04-1). Consecutive
dosing was separated by a drug-free wash-out period of 7 d. Following each dosing,
serial venous blood samples were collected over a period of 48 h for the determination
of plasma rilmenidine concentrations by means of a validated LC-MS/MS method. The
most frequently reported drug-related adverse events were dizziness and headache ranging
from mild to moderate in intensity. The geometric mean Cmax of rilmenidine for the reference and test products was 3.73 and 3.97 ng/ml, respectively.
The corresponding geometric mean AUC(0–∞) was 34.0 and 35.1 ng • h/ml. Tmax for both products under investigation appeared at 1.33 h. The test product was shown
to be bioequivalent to the reference product with respect to all pharmacokinetic variables
investigated.
Key words
Antihypertensive agents - CAS 54187-04-1 - CAS 85409-38-7 - Hyperium® - Rilmenidine,
bioavailability, bioequivalence, pharmacokinetics - Rilmenidine dihydrogen phosphate
